Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: The SPHERE Study

Expert Review of Neurotherapeutics

Volumn 9, Issue 10, 2009, Pages 1463-1474

  De La Gándara, Jesús ^a   San Molina, Luis ^b   Rubio, Gabriel ^c   Rodriguez Morales, Alexander ^d   Borrajo, Rebeca Hidalgo ^d   Burón, José Antonio ^d  

^a Hospital Divino Valles   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d Medical Department   (Spain)

Author keywords

Acute hospitalization; Antipsychotic; Depot formulation; Intramuscular; Long acting; Patient compliance; Risperidone; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLOTIAPINE; CLOZAPINE; CONSTA; FLUPHENAZINE; HALOPERIDOL; HYPNOTIC AGENT; LEVOMEPROMAZINE; LONG ACTING DRUG; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; UNCLASSIFIED DRUG; ZIPRASIDONE; ZUCLOPENTHIXOL;

ACUTE DISEASE; ADULT; AGED; AKATHISIA; ARTICLE; CAREGIVER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SAFETY; DYSARTHRIA; EMERGENCY CARE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSPITALIZATION; HUMAN; IMPOTENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT ATTITUDE; PRESCRIPTION; RELATIVE; SCHIZOPHRENIA; SOMNOLENCE; SPAIN; TREMOR;

ADULT; COHORT STUDIES; DOPAMINE ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; INJECTIONS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; SPAIN; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 70350167140     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.96     Document Type: Article

References (39)

1. Schultz SH, North SW, Shields CG. Schizophrenia: a review. Am. Fam. Physician 75(12), 1821-1829 (2007).
2. Remington GJ, Collins A. Video workshop: an educational intervention to enhance compliance in schizophrenia. Presented at: Research Program and Abstracts of the 53rd Annual Meeting of the American Psychiatric Association Institute on Psychiatric Services. Orlando, FL, USA, 10-14 October 2001.
3. Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res. 161(2), 235-247 (2008).
4. Hogarty GE, Schooler NR, Ulrich R et al. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch. Gen. Psychiatry 36(12), 1283-1294 (1979). (Pubitemid 11145664)
5. Hogarty GE, Ulrich RF. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J. Psychiatr. Res. 32(3-4), 243-250 (1998).
6. Marland GR. Atypical neuroleptics: autonomy and compliance? J. Adv. Nurs. 29(3), 615-622 (1999).
7. Kemp RA, David AS. Insight and adherence to treatment in psychotic disorders. Br. J. Hosp. Med. 54(5), 222-227 (1995).
8. Möller HJ. Antipsychotic agents. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot. Eur. Psychiatry 20(5-6), 379-385 (2005).
9. Remington GJ, Adams ME. Depot neuroleptic therapy: clinical considerations. Can. J. Psychiatry 40(3 Suppl. 1), S5-S11 (1995).
10. Barnes TR, Curson DA. Long-term depot antipsychotics: a risk-benefit assessment. Drug Saf. 10(6), 464-479 (1994).
11. National Institute for Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. Clinical guideline 1. NICE, London, UK (2002).
12. Serretti A, De Ronchi D, Lorenzi C, Berardi D. New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr. Med. Chem. 11(3), 343-358 (2004). (Pubitemid 38240211)
13. Möller HJ. Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs 17(11), 793-823 (2003).
14. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361(9369), 1581-1589 (2003). (Pubitemid 36578993)
15. Csernansky JG, Mahmoud R, Brenner R; Risperidone-USA-79 study group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 346(1), 16-22 (2002). (Pubitemid 34438915)
16. Moore DB, Kelly DL, Sherr JD et al. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Am. J. Health Syst. Pharm. 55(24 Suppl. 4), S17-S19 (1998).
17. Ereshefsky L, Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs R. D. 6(3), 129-137 (2005). (Pubitemid 40994250)
18. Medori R, Mannaert E, Gründer G. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long acting injectable. Eur. Neuropsychopharmacol. 16(4), 233-240 (2006).
19. Ehret MJ, Fuller MA. Long-acting injectable risperidone. Ann. Pharmacother. 38(12), 2122-2127 (2004).
20. Knox ED, Stinmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin. Ther. 26(12), 1994-2002 (2004).
21. Lindenmayer JP, Jarboe K, Bossie CA et al. Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int. Clin. Psychopharmacol. 20(4), 213-221 (2005). (Pubitemid 40896376)
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th Edition). American Psychiatric Association, Washington, DC, USA (1994).
23. Bai YM, Ting Chen T, Chen JY et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J. Clin. Psychiatry 68(8), 1218-1225 (2007).
24. Kiivet RA, Llerena A, Dahl ML et al. Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. Br. J. Clin. Pharmacol. 40(5), 467-476 (1995).
25. Thusholt FJ, Jensen EO, Knop J et al. Use of psychiatric emergency clinics in Copenhagen and Frederiksberg by schizophrenic patients. Ugeskr. Laeger. 155(19), 1459-1463 (1993).
26. Sanguinetti VR, Samuel SE, Schwartz SL, Robeson MR. Retrospective study of 2,200 involuntary psychiatric admissions and readmissions. Am. J. Psychiatry 153(3), 392-396 (1996).
27. De las Cuevas C, Sanz EJ. Polypharmacy in psychiatric practice in the Canary Islands. BMC Psychiatry 4, 18 (2004).
28. Faries D, Ascher-Svanum H, Zhu B et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 5, 26 (2005). (Pubitemid 41460700)
29. Santamaria B, Perez M, Montero D et al. Use of antipsychotic agents in Spain through 1985-2000. Eur. Psychiatry 17(8), 471-476 (2002).
30. Mauri MC, Turner M, Volonteri LS, Medori R, Maier W. Dosing patterns in Europe: Efficacy and safety of risperidone long-acting injectable in doses of 25, 37.5 and 50 mg. Int. J. Psychiatry Clin. Pract. 13(1), 36-47 (2009).
31. Möller HJ, Llorca PM, Sacchetti E, Matin SD, Medori R, Parellada E. StoRMi study group: efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int. Clin. Psychopharmacol. 20(3), 121-130 (2005). (Pubitemid 40571509)
32. Masand PS. A review of pharmacologic strategies for switching to atypical antipsychotics. Prim. Care Companion J. Clin. Psychiatry 7(3), 121-129 (2005).
33. Bowers L, Callaghan P, Clark N, Evers C. Comparisons of psychotropic drug prescribing patterns in acute psychiatric wards across Europe. Eur. J. Clin. Pharmacol. 60(1), 29-35 (2004). (Pubitemid 38471455)
34. Edlinger M, Hausmann A, Kemmler G et al. Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophr. Res. 77(1), 25-34 (2005). (Pubitemid 40957058)
35. Llorca PM, Bouhours P, Moreau-Mallet V. Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone. Encephale 34(2), 170-178 (2008). (Pubitemid 351621977)
36. Olivares JM, Rodriguez-Morales A, Diels J et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic schizophrenia treatment adherence registry (e-STAR). Eur. Psychiatry 24(5), 287-296 (2009).
37. Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez- Morales A; on behalf of the e-STAR Study Group. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl. Health Econ. Health Policy 6(1), 41-53 (2008).
38. Vicente J, Hernández H, De la Gándara J. Tratamiento con risperidona de liberación prolongada en pacientes hospitalizados por trastornos psicóticos. Psiq. Biol. 13(2), 47-52 (2006). (Pubitemid 43953779)
39. American Psychiatric Association Practice Guidelines. Treatment of patients with schizophrenia (2nd Edition) (2004) www.psychiatryonline.com/ pracGuide/pracGuideTopic-6.aspx